
Oncology NEWS International
- Oncology NEWS International Vol 5 No 1
- Volume 5
- Issue 1
Zoladex Gets Indication for Advanced Breast Ca
WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals' gonadotropin-releasing-hormone (GnRH) agonist, has received approval for use in the treatment of advanced breast cancer in premenopausal and perimenopausal women.
WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals'gonadotropin-releasing-hormone (GnRH) agonist, has received approvalfor use in the treatment of advanced breast cancer in premenopausaland perimenopausal women.
The agent was introduced in the United States for the treatmentof advanced prostate cancer in 1989 and for the treatment of endometriosisin 1993.
Zoladex, given by injection once a month, acts on the pituitarygland to cause decreased production of estrogen by the ovaries.This lowers serum estrogen levels to concentrations typical ofpostmenopausal women, reducing estrogen stimulation of breasttumor growth.
The new indication is based on results of clinical trials involvingmore than 800 women in North America and Europe, showing responserates and survival benefits comparable to those achieved by oophorectomy,the company said.
Articles in this issue
about 30 years ago
HCFA Reevaluations May Affect Chemo Administration Cost Codesabout 30 years ago
Breast Cancer Info Now on Internetabout 30 years ago
HDC/ABMT Has Benefits in Multiple Myelomaabout 30 years ago
Reporting of Study Comparing Casodex, Eulexin Is Questionedabout 30 years ago
Limits on Tamoxifen Duration Questionedabout 30 years ago
ACRO Forecasts Radiologist Surplusabout 30 years ago
Potency Status Before RT, Not Dose, Determines Post-RT Functionabout 30 years ago
Dr. Klausner Outlines Goals for NCIabout 30 years ago
Difficulties in Translating Relative Risks Into Absolute RiskNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


































